Buying Modafinil online has become increasingly popular, with many buyers opting for Bitcoin as a secure and anonymous ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

From baseline, patients treated with AXS-12 had an 83% reduction in cataplexy attacks at the end of 5 weeks compared with a 66% reduction with placebo (rate ratio [RR] 0.49, P=0.0 ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.

Avadel has initiated four patent infringement lawsuits against Jazz Pharmaceuticals since the beginning of 2025, alleging certain uses of Jazz’s Xywav product, according to its corresponding labeling, ...

Healthcare Analysts, along with Dr. Kiran Maski discuss Narcolepsy on an Analyst/Industry conference call to be held on April 11 at 11 am. Stay ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...